FDA Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Arthritis Immunology
Research from Hospital for Special Surgery has provided new data on arthritis immunology
March 15th, 2007
A report, "Suppression of the effector phase of inflammatory arthritis by double-stranded RNA is mediated by type I IFNs," is newly published data in The Journal of Immunology. According to a study from the United States, "Innate immune receptors that recognize nucleic acids, such as TLRs and RNA helicases, are potent activators of innate immunity that have been implicated in the induction and exacerbation of autoimmunity and inflammatory arthritis. Polyriboinosine-polyribocytidylic acid sodium salt (poly(IC)) is a mimic of dsRNA and viral infection that activates TLR3 and the RNA helicases retinoic acid-induced gene-1 and melanoma differentiation-associated gene-5, and strongly induces...
Source: FDA Law Weekly (2007-03-15)
|
